ArticleJournal of nanobiotechnology2026
Cerium-doped prussian blue nanozymes for bone regeneration and osteoprotection by Lhx2 in sutural distraction osteogenesis through multi-omics analysis.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanozymes for Bone Regeneration: Mechanistic Insights into Immune and Metabolic Microenvironment Modulation.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Sutural distraction osteogenesis (SDO) involves the induction of new bone formation in the suture region through external distraction, widely employed for treating craniomaxillofacial deformities such as craniosynostosis and maxillary transverse hypoplasia. Nonetheless, there remains a deficiency in effective and minimally invasive therapeutic approaches to shorten the treatment duration and minimize the risk of relapse. Prussian blue (PB) nanozymes exhibit extensive biological applications due to their superior biocompatibility and enzyme-like activity. Incorporating cerium (Ce), which possesses REDOX and osteopromoting properties, into Prussian blue nanozymes not only preserves its excellent biosafety but also enhances stem cell recruitment and bidirectional regulation of osteogenesis promotion and osteoclast inhibition. Moreover, the bidirectional regulatory effects of cerium-doped prussian blue (CePB) nanozymes are significantly amplified under mechanical tension conditions. ANANSE (Analysis Algorithm for Networks Specified by Enhancers) analysis integrating RNA-seq, ATAC-seq, and CUT&Tag data identified Lhx2 as a critical transcription factor involved in regulating osteogenic differentiation of suture‑derived stem cells (SuSCs) mediated by CePB nanozymes, which was further validated in vitro. In summary, CePB nanozymes offer a novel adjuvant therapy for craniomaxillofacial suture distraction osteogenesis. This study provides the first in-depth, comprehensive, and reliable investigation into how nanozymes regulate stem cell fate through the integration of transcriptome analysis and epigenetic sequencing.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.